Static daily chart from Finviz (click to open the full interactive chart on Finviz Elite – affiliate link).
Alvotech (ALVO) – Daily Hit: pivotal PK success for Entyvio biosimilars AVT16/AVT80
Global biosimilar pure play turns a pivotal PK study into the next leg of its Entyvio offensive.
Ticker: ALVO (NASDAQ)
Theme: Biosimilars, IBD, Entyvio (vedolizumab)
Focus: AVT16 / AVT80 pivotal PK study
Language toggle – content below switches between English and Italian.
Setup: profitable biosimilar platform with heavy debt but real revenues
Today’s trigger: pivotal PK study AVT80-GL-P01 hits all endpoints
Angle: Entyvio ~6.4B$ market, dual IV/SC biosimilar strategy, regulatory filings next.
Last close (Nasdaq)
~5.0–5.1 USD
Small/mid-cap biotech; intraday spike on PK news, closing roughly flat vs pre-PR levels.
Scale & profitability
Revenues ~339M$ (9M 2024)
Adjusted EBITDA ~87M$, operating profit ~56M$ for 9M 2024; platform is past “pre-revenue” stage.
Balance sheet snapshot
Cash ~118M$ / Debt ~1.0B$
Highly leveraged, recently added a 100M$ term loan; liquidity OK but debt is part of the story.
1. Why ALVO is on the radar today
Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.
Today’s move is all about the Entyvio franchise. The pivotal AVT80-GL-P01 pharmacokinetic study, designed to compare AVT80 – Alvotech’s proposed subcutaneous vedolizumab biosimilar – to branded Entyvio in healthy adults, met all primary endpoints for PK and also delivered clean safety, tolerability and immunogenicity signals. Based on regulatory advice, this single PK study is considered pivotal for both AVT80 (SC) and AVT16 (IV), effectively unlocking the path toward regulatory submissions for two formulations off one core data package.
On top of that, earlier this week Alvotech announced new supply and commercialization agreements with Sandoz covering Canada and Australia/New Zealand for multiple biosimilar candidates, extending a commercial footprint that already spans Europe, Japan and North America. For a stock that has traded mostly as a “levered execution story”, today’s tape adds a cleaner clinical milestone and a reminder of the size of the Entyvio opportunity (~6.4B$ 2025 net sales for the reference product).
2. What exactly happened in the AVT80 PK study
The AVT80-GL-P01 trial is a randomized, double-blind, single-dose, three-arm parallel-group PK study in healthy adults. Participants received a single 108 mg / 0.68 mL subcutaneous injection of either AVT80 or Entyvio, and the protocol was designed to demonstrate pharmacokinetic similarity and to assess safety, tolerability and immunogenicity. According to the company, AVT80 met all primary PK endpoints versus Entyvio and showed comparable safety and immunogenicity profiles in this healthy-volunteer setting.
The key nuance is regulatory: Alvotech states that, based on prior regulatory advice, the AVT80-GL-P01 study satisfies the demonstration of PK similarity to Entyvio for both administration routes – subcutaneous and intravenous. In other words, this single PK package is meant to serve as the pivotal clinical pharmacology backbone for both AVT80 (SC) and AVT16 (IV), with AVT16 supported further by an ongoing phase 3 patient study in ulcerative colitis.
3. Entyvio market size and why a biosimilar matters
Entyvio (vedolizumab) is a gut-selective monoclonal antibody used to treat moderate-to-severe ulcerative colitis and Crohn’s disease. It is a chronic, high-value therapy where patients can stay on treatment for years, and the reference product generated approximately 6.4B$ of net revenues worldwide in 2025.
From a trading perspective, that matters for two reasons. First, it means that even a single-digit market share for a biosimilar can translate into meaningful recurring revenue for a company the size of Alvotech. Second, dual-route development (IV and SC) aligns the product profile with how Entyvio is actually used in practice, increasing the chances of being competitive in tenders and payer negotiations once patents and exclusivity barriers fall away in key markets.
4. Where AVT16 / AVT80 sit in the broader pipeline
The Entyvio program is one branch of a larger biosimilar tree. Alvotech’s late-stage assets include:
AVT02 – adalimumab biosimilar now launched in the US and multiple ex-US markets, a key driver of current product revenue.
AVT04 – ustekinumab biosimilar with approvals and launches across Europe, Canada, Japan and other regions.
AVT03 / AVT05 / AVT06 – other immunology and oncology biosimilars where phase 3 data and regulatory filings have already triggered significant milestone revenue from partners.
AVT16 / AVT80 – vedolizumab IV/SC pair now de-risked on PK with today’s read-out and supported by an ongoing phase 3 patient study for AVT16.
Taken together, this is a pipeline where multiple assets are already contributing product sales and milestones, with Entyvio framed as one of the next big legs in the growth story.
5. Balance sheet, leverage and execution risk
The downside of building a global biosimilar platform is capital intensity. As of the latest reported nine-month period (to 30 September 2024), Alvotech carried roughly 1.0B$ of borrowings against about 118M$ of cash and cash equivalents. The company has since added an additional 100M$ senior term loan facility, strengthening liquidity but also reinforcing the “levered” nature of the equity.
On the positive side, the P&L has flipped into the black on adjusted EBITDA and operating profit, helped by the ramp of AVT02/AVT04 and sizable milestone recognition from pipeline progress. The bear counter-argument is that high interest costs and the need to keep funding new launches and manufacturing scale-up can absorb a lot of that operating profit, leaving equity holders exposed if execution slips or if pricing pressure in biosimilar tenders is more aggressive than expected.
6. Retail sentiment and tape behaviour
Retail sentiment is skewed positive after the PK news. On Stocktwits, the ALVO stream is dominated by posts highlighting the 6.4B$ Entyvio market and the word “pivotal” in the press release. The tone is more “long-term potential” than detailed modelling, but the bias is clearly bullish and focused on upside if the Entyvio program eventually turns into actual approved products.
On Reddit and X, traffic is lighter but still supportive: ALVO tends to appear in threads about biosimilar pure plays and “platform stories” rather than meme-stock clusters. Importantly, most comments come from non-professional traders and do not constitute research or regulated investment advice – they are useful to gauge enthusiasm and crowd positioning, not to build a DCF.
7. Catalyst map and what to watch next
- Near-term: more detailed PK data from AVT80-GL-P01 in conferences or publications, clarification of regulatory filing sequence for AVT16 (IV) and AVT80 (SC).
- 2026: progress updates on the AVT16 phase 3 ulcerative colitis study and any regulatory submissions for Entyvio biosimilars in major markets (EU, US, others), subject to agency feedback.
- Ongoing: commercial ramp of existing launched biosimilars (AVT02, AVT04) and new territory launches; monitoring of pricing dynamics and gross margins as tenders roll over.
- Financing side: any refinancing or debt-structure news given the current >1B$ borrowings and the extra 100M$ term loan, plus potential equity issuance if the company chooses to de-lever.
For a trader, this sets up ALVO as a name where single news items (regulatory filings, trial read-outs, big-ticket tenders) can move the stock sharply in either direction, against a backdrop of real revenue and real leverage rather than a binary “all or nothing” phase 2 biotech.
8. Run-up / trading angle (educational only)
From a purely educational, non-advisory perspective, ALVO sits in the bucket of “levered biosimilar platform with multiple shots on goal”. The Entyvio PK win removes a key uncertainty around the clinical backbone for AVT16/AVT80, but the bigger value unlock still lies ahead at the level of regulatory decisions, pricing, tender wins and actual market penetration.
In a classic catalyst-driven “run-up” framework, traders may watch three layers at once: (1) concrete news milestones (regulatory submissions, major approvals or label decisions), (2) execution signals from the core commercial biosimilar portfolio, and (3) balance sheet moves that change the equity risk profile. None of these should be treated as buy/sell signals on their own – they are simply pieces of information to be weighed against individual risk tolerance and time horizon.
Key primary sources used for this Daily Hit (selection):
- Alvotech press release – positive top-line results from pivotal PK study AVT80-GL-P01 for proposed Entyvio biosimilar (GlobeNewswire / company IR).
- Form 6-K filed with the SEC summarising the same AVT80 study and its pivotal status for AVT16/AVT80.
- Alvotech press release and 6-K on financial results for the first nine months of 2024 (revenues, EBITDA, cash, debt).
- Alvotech press release / 6-K on the 100M$ senior term loan facility signed in late 2025.
- Alvotech & Sandoz press release on supply/commercialization agreements for Canada and Australia/New Zealand covering multiple biosimilar candidates.
- Entyvio (vedolizumab) revenue disclosure for 2025 net worldwide sales (company disclosures summarised in the PK press release).
Biotech Catalyst Calendar
For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical read-outs, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.